. 2024 Mar 14;84(3):285–304. doi: 10.1007/s40265-024-02011-w

Table 2.

Pre-treatment testing and safety monitoring for anti-CD20 monoclonal antibody therapy

Contraindications	Active hepatitis B infection^a
	History of life-threatening infusion reaction to medication^b
Recommended pretreatment testing^a	Complete blood count with differential
	Comprehensive metabolic panel
	Quantiferon/tuberculosis screen
	Hepatitis panel
	Varicella zoster virus IgG (to ensure immunity)
	Quantitative Ig levels
	Urine or serum beta human chorionic gonadotropin (where appropriate)
	Brain MRI
	All necessary vaccinations > 4 weeks prior to first dose
Recommended monitoring schedule^a	Complete blood count with differential (every 6 months)
	Comprehensive metabolic panel (every 6 months)
	CD19 count (every 6 months)
	Quantitative Ig levels (every 6 months)
	Monitor for recurrent or serious infection
	Monitor for malignancy/ensure all age-appropriate cancer screening up to date
Pregnancy and family planning	Recommend contraception during treatment and for 6 months after^a

CD20 cluster of differentiation-20, CD19 cluster of differentiation–19, Ig immunoglobulin, MRI magnetic resonance imaging

^aFor rituximab [16], ocrelizumab [18], ofatumumab [32], and ublituximab [74]

^bFor rituximab [16], ocrelizumab [18], and ublituximab [74]